Main Article Content
Chronic inflammatory bowel diseases, namely ulcerative colitis and Crohn’s disease, attracted the attention of both doctors and scientists all over the world. There was a trend to an increase in the number of severe, treatment-resistant forms of diseases, complications and surgical interventions that lead to disability in the young, working-age patients. The article shows the problems in the diagnosis of chronic inflammatory bowel diseases (ulcerative colitis, Crohn’s disease).The possibilities of instrumental and laboratory methods of study are shown. Attention is paid to non-invasive diagnostic methods — determination of faecal calprotectin, lactoferrin, lysozyme, elastase, myeloperoxidase, A1-antitrypsin. A literature search was conducted using databases Pub Med, MedLine, EMBASE.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Adler G. Bolezn Krona і yazvennіy kolіt [Crohn’s disease and ulcerative colitis]. Moscow: GEOTAR-MED; 2001. 528 p. (in Russian).
Ivashkin VT, Shifrin OS. Contemporary approaches to the treatment of Crohn’s disease. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2002;2:67-73. (in Russian).
Belousov EA. Yazvennіy kolіt I bolezn Krona [Ulcerative colitis and Crohn’s disease]. Tver: Triada; 2002. 128 p. (in Russian).
Stepanov YuM, Fedorova NS. The real state and prospects in the diagnostics of intestinal diseases. Suchasna gastroenterologyja. 2010;1(51):109-114. (in Ukrainian).
Stepanov YuM, Scherbynina MB, Kononov IN. Suchasni metodi doslidgenya v gastroentorologii: Metod. posib. [Contemporary methods in gastroenterology. Guidelines]. Dnipropetrovs’k; 2006. 155 p. (in Ukrainian).
Stepanov Yu.M., BoykoT.Y. Chvoroba Krona: suchasni pidchodi do diagnostiki ta likuvannya [Crohn’s disease: contemporary approaches to diagnostics and treatment]. Dnipropetrovs’k; 2014. 31 p. (іn Ukrainian).
Mostovoy YuM. Suchasni klasifikacii ta standarti likuvannya rozpovsudgenich zachvoruvan vnutrishnich organiv [Contemporary standards of classification and treatment of internal diseases of internal organs]. Vinnitsa; 2008. 462 p. (іn Ukrainian).
Svintsitskyi AS. Diagnostika ta likuvannya poshirenich zachvoruvan organiv travlennya: Navchalniy posibnik [Diagnosis and treatment of common diseases of the digestive system. Guidelines]. Kyiv: Medknyha; 2007. 296 p. (іn Ukrainian).
Marzhatka Z. Terminologiya, opredelenie terminov i diagnosticheskie kriterii v endoskopii pishevaritelnogo trakta [Terminology, definitions and diagnostic criteria in the endoscopy of the digestive tract]. Hamburg (Germany): Normed Verlag; 1996. 123 p.
Nozdrin VI. Express histologiya [Express histology]: Uchebnoe posobie. Manual, 4th edition, enlarged, revised. Moscow: “Honey. Inf. Agency”; 2008. 208 p. (іn Russian).
Sergienko AI. Ranni proyavi I difirenciyna diagnostika chronichnih zapalnih zahvoruvan kishechnika [Early manifestations and differential diagnostics of chronic inflammatory bowel diseases]. Zaporozhye: Wild Field; 2005. 157-163 p. (іn Ukrainian).
Vasilchenko AV. Ways of improving of the efficiency of diagnostics of diseases of the colon during colonoscopy. Abstract; 2002. 19 р.
Grigoriev G. Functional constipation and irritable bowel syndrome: differential diagnosis and treatment. Vrach. 2006;2:3-6. (іn Russian).
Krylova EA. Changes of biochemical parameters in Crohn’s disease and ulcerative colitis. Clean. hir. 2003;11:153-155. (іn Ukrainian).
Golysheva SV, Meshalkina IY, Grigorieva GA. Valuation and forecasting of quality of life in patients with inflammatory bowel disease as a result of long-term monitoring. Gastrojenterologija. 2005;1-2:32-36. (іn Russian).
Grigoriev PY, Ivashkin VT, Komarov FI. Standards (protocols) of diagnostics and treatment of diseases of the digestive system. Praktikujushhij vrach. 1998;2:2-13. (in Rusian).
Zvyagintseva TD, Grydnyeva SV. Contemporary approaches to diagnosis of chronic bowel disease. Ukr. therapeutic journal. 2005;2:44-48. (in Ukrainian).
Komarov FI, Osadchuk AM, Osadchuk MA. Nespecificheskiy yazvenniy kolit [Ulcerative colitis]. M.: Medical News Agency Ltd; 2008. 256 p. (in Russian).
Lazebnik L, Huseynov ZM, Efremov LI. Fecal calprotectin as a biomarker of the effectiveness of various medical vmeschatelstv in patients with inflammatory diseases kishechnika. Eksperimentalnaya i klinicheskaja gastrojenterologija. 2013;8.
Langhorst J, Elsenbruch S, Koelzer J, Rueffer А, Michalsen А, Dobos G. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. J Gastroenterol. 2008;103:162-9. doi: 10.1111/j.1572-0241.2007.01556.x.
Lorens MH. Inflammatory bowel disease. Lab. Diagnostics. 2001;40.
Saverymuttu SH, Camilleri M, Rees H, et al. Indium 111 Granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal Indium 111Granulocyte Excretion. Gastroenterol. 1986;90:1121-8.
Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol. 2002;14(4):409-12.
Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11):1518-23. doi: 10.1136/gut.2007.146357. Epub 2008 Jun 19.
Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-protein serum level. Inflamm Bowel Dis. 2007;13:1100-5. doi: 10.1002/ibd.20178.
Angriman I, Scarpa M, D’Incà R, Basso D, Ruffolo C, Polese L, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007;381:63-8. doi: 10.1016/j.cca.2007.02.025.
Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D. et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-14. doi: 10.1111/j.1572-0241.2003.07458.x.
Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32-9. doi: 10.1002/ibd.20275.
Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58(2):176-80. PMID: 9144308
Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with infl ammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-20. doi: 10.1080/00365520410007971.
Tibbie JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal infl ammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15-22. PMID: 10889150
Otten CM, Kok L, Witteman BJ et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bower syndrome. Clin Chem Lab Med. 2008;46(9):1275-1280. doi: 10.1515/CCLM.2008.246.
Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1755-62. doi: 10.1111/j.1572-0241.2002.05837.x.
Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjö H, Carlson M. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest. 2007;67:810-20. doi: 10.1080/00365510701452838.
Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584-9. PMID: 18810778